Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

References

• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):1–7. PMID: 32007143. doi:10.1016/S0140-6736(20)30211-7.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. PMID: 31978945. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 dashboard. 2020 [accessed 2022 June 14].
   Google Scholar
• Zhao S, Zhuang Z, Ran J, Lin J, Yang G, Yang L, He D. The association between domestic train transportation and novel coronavirus (2019-nCov) outbreak in China from 2019 to 2020: a data-driven correlational report. Travel Med Infect Dis. 2020;33:101568. PMID: 32006656. doi:10.1016/j.tmaid.2020.101568.
   PubMed Web of Science ®Google Scholar
• Wang X, Pan Z, Cheng Z. Association between 2019-nCov transmission and N95 respirator use. J Hosp Infect. 2020;105(1):104–05. PMID: 32142885. doi:10.1016/j.jhin.2020.02.021.
   PubMed Web of Science ®Google Scholar
• Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2021;395(10223):514–23. PMID: 31986261. doi:10.1016/S0140-6736(20)30154-9.
   Web of Science ®Google Scholar
• Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–51. PMID: 32035997. doi:10.1016/j.jhin.2020.01.022.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. PMID: 32109013. doi:10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. PMID: 31986264. doi:10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–69. PMID: 32031570. doi:10.1001/jama.2020.1585.
   PubMed Web of Science ®Google Scholar
• Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden CR, Zhang J, et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg Infect Dis. 2020;26(6):1266–73. PMID: 32160149. doi:10.3201/eid2606.200516.
   PubMed Web of Science ®Google Scholar
• Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCov) in Wuhan, China. J Med Virol. 2020;92(4):441–47. PMID: 31994742. doi:10.1002/jmv.25689.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 vaccine tracker and landscape. 2021 [accessed 2022 May 05]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–84. PMID: 34774196. doi:10.1016/S0140-6736(21)02000-6.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) covid-19 vaccine. N Engl J Med. 2021;385(25):2348–60. PMID: 34587382. doi:10.1056/NEJMoa2105290.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. PMID: 33545094. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853. PMID: 33059771. doi:10.1186/s13063-020-04775-4.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 dashboard. 2020 [accessed 2022 July 03]. https://covid19.who.int/ .
   Google Scholar
• Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. PMID: 34246358. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):6520–28. PMID: 34620531. doi:10.1016/j.vaccine.2021.09.052.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in chile. N Engl J Med. 2021;385(10):875–84. PMID: 34233097. doi:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• China National Medical Products Administration. Guidelines for grading standards of adverse events in clinical trials of preventive vaccines. 2019 [accessed 2022 July 03]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20191231111901460.html.
   Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181–92. PMID: 33217362.
   PubMed Web of Science ®Google Scholar
• SINOVAC. Inactivated COVID-19 vaccine, CoronaVac has been added to the WHO’s emergency use list for one year. 2020 [accessed 2022 July 14]. https://mp.weixin.qq.com/s/YdlwKsOlq9JezrgrYhHFBg.
   Google Scholar
• Camacho Moll ME, Salinas Martínez AM, Tovar Cisneros B, García Onofre JI, Navarrete Floriano G, Bermúdez de León M. Extension and severity of self-reported side effects of seven COVID-19 vaccines in Mexican population. Front Public Health. 2022;10:834744. PMID: 35359754. doi:10.3389/fpubh.2022.834744.
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, Chen HX. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891–98. PMID: 33929930. doi:10.1080/14760584.2021.1925112.
   PubMed Web of Science ®Google Scholar